← Leaderboards
Omar Abousaway
Washington University
$69,810
Attributed
$69,810
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $35.2K · FY2024–25$50K$37.5K$25K$12.5K$0
'24
'25
Funding mix
By agency
NIH$69,810 · 1
By mechanism
F31$69,810 · 1
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- Emil R Unanue$30,520,501
- Paolo Provenzano$10,825,017
- Marco Colonna$45,277,211
- David G Denardo$14,438,310
- Kenneth M. Murphy$11,514,927
Others in their field
Other Rising Stars on “Antigen-Presenting Cells”
- Dmitriy Zamarin · Sloan-Kettering Inst Can Research$3,530,063
- Reeder McNeil Robinson · Leukogene Therapeutics, Inc.$2,940,211
- Stephen Starko Francis · University Of California, San Francisco$2,607,031
- Chrysothemis Brown · Sloan-Kettering Inst Can Research$2,124,000
- Leyuan Ma · Children'S Hosp Of Philadelphia$2,109,666
- Shivashankar Othy · University Of California-Irvine$1,988,640
Research focus
Antigen-Presenting CellsAntigensAutoantigensAutoimmuneAutoimmune DiabetesAutoimmune DiseasesAutoimmune ResponsesAutoimmunityAutoreactive T CellAutoreactivityBcl2 GeneBindingB-LymphocytesCd3 AntigensCd4 Positive T LymphocytesCd8-Positive T-LymphocytesCell CountCell Death InductionCellsCell TypeCessation Of LifeChemokine ReceptorChildhoodAntigen Presentation
Grant awards (2)
Targeting cDC1 with CAR T cells to investigate their role and potential as a therapeutic target in Type 1 diabetes$35,187
F31 · FY2025 · DK · contact PI
Targeting cDC1 with CAR T cells to investigate their role and potential as a therapeutic target in Type 1 diabetes$34,623
F31 · FY2024 · DK · contact PI